Blue Jet Health Q1 FY27 Earnings Call — Analysis (NSE: BLUEJET)
Blue Jet Q1 sees 25% sequential revenue growth driven by PI recovery; strategic expansion projects on track
The take
Q1FY27 Revenue ₹293 Cr ( +25% QoQ ) . New guidance — FY27 fy27 capex ₹250 Cr . New story: PI recovery and order-book visibility .
Results
Revenue ₹293 Cr up 25% QoQ; EBITDA margin 33.5% (+310 bps QoQ); gross margin 53% (-300 bps QoQ)
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹293 Cr | +25% | qoq · Q1FY27 |
| Gross Margin | 53% | −300 bps | qoq · Q1FY27 |
| EBITDA Margin | 33.5% | +310 bps | qoq · Q1FY27 |
| PAT Margin | 26.7% | −70 bps | qoq · Q1FY27 |
| FY27 Capex Guidance | ₹250 Cr | point_in_time · FY27 · expected spend FY27 | |
| Vizag Phase 1 Investment | ₹1,000 Cr | point_in_time · FY27-FY29 · over next 3 years |
Guidance
FY27 capex ~₹250 Cr; Vizag Phase 1 ₹1,000 Cr over 3 years; Unit 3 backward integration commercial in H2 FY27
What management committed to
- [Unit 3 Mahad backward integration project] will have commercial contribution during the second half of FY27 — H2FY27
- Capital expenditure for [Blue Jet overall] in FY27 will be approximately ₹250 Cr — ₹250 Cr, FY27
- Phase 1 of [Vizag] project represents an investment of approximately ₹1,000 Cr over the next 3 years — ₹1,000 Cr, FY29
- [Blue Jet] expects to launch 3 candidates within the Contrast Media segment during FY27 — 3, FY27
- At least 2 high-conviction NCE programs in chronic therapy space will fructify by FY28 — at least 2, FY28
- [PI intermediate business] performance can be sustained for full year FY27 — FY27
- Commercial batches of iodinated contrast media intermediate will begin by end Q2 or early Q3 FY27 — Q2FY27
- [Blue Jet] will not participate in the front-end generic peptide opportunity; will focus on peptide fragments and selective CDMO for innovators
Key themes
PI recovery and strategic CDMO platform build-out
How the narrative shifted
- PI recovery and order-book visibility: Management emphasizes that destocking headwinds are behind and the PI intermediate business has strong multi-quarter visibility with secular end-market growth, reinforcing confidence in near-term performance.
- CDMO platform build-out (Vizag, R&D): The Vizag megaproject and new R&D centre are positioned as a long-term platform play for multiple chemistry types, enabling larger, longer-duration contracts with global innovators.
- Contrast media backward integration: Unit 3 Mahad is ahead of schedule and will make Blue Jet one of the most vertically integrated players, improving cost competitiveness and supply security.
- Raw material cost volatility: Geopolitical situation has driven broad raw material price increases; management flags uncertainty and a lagged pass-through mechanism, though customers are described as supportive.
- Platform diversification into peptides/GLP-1: Management is actively building peptide fragment capabilities and integrating them into Vizag, while explicitly avoiding commoditized generic peptides to protect margins.
- Geopolitical supply-chain friction: Container shortages and longer transit times caused goods-in-transit delays, compressing recognized contrast media revenue; seen as transient but part of the operating environment.
Operational commentary
- PI and API segment recovery: intermediate supply restarted after destocking; strong order book, visibility sustained for FY27
- Contrast media revenue declined 40% QoQ largely due to goods-in-transit delays (~₹30 Cr higher closing stock); production steady at ~70% utilization
- Unit 3 Mahad backward integration for contrast media ahead of schedule; commercial contribution now expected H2 FY27 (earlier guided H2 CY); ₹210 Cr invested, ₹40 Cr more to complete phase
- Vizag Phase 1: consent to establish secured, engineering progressing; ~100 acres, multi-purpose GMP intermediates, complex APIs, CDMO capacity; designed for flexibility including high potency, multiple chemistry platforms
- Hyderabad R&D centre Phase 1 operational this month; focus on peptides, GLP-1 intermediates, biocatalysts, continuous manufacturing & flow synthesis; critical scientific talent onboarded
- Product pipeline: 3 new contrast media candidates to launch in FY27; pilot validation for new high-intensity sweetener underway; 4 high-conviction NCE programs (chronic therapies, oncology, CNS) progressing through customer development
- Mahad capex to also enable third-party supply of select upstream contrast-media intermediates, creating additional revenue opportunity over time
Analyst Q&A
Q. Quantify the contrast media revenue deferred due to goods in transit and current utilization levels
Goods in transit higher by ~₹30 Cr vs opening cut-off; production steady at ~70% utilization, dispatches at 100%
Q. Visibility and sustainability of PI API revenue after sharp Q1 jump
Strong order book; consistent production; good visibility for next 3-4 quarters; end-market secular growth
Q. Whether PI API supply includes Japan and details on new molecules/lateral entries in PI segment
Will guide at appropriate time; currently only comment on strong order book and global qualifications
Q. Competitive threat from Divis Labs' entry into iodine-based contrast media
Difficult to answer without knowing the company; not giving customer-specific guidance
Q. Number of RFPs in peptides/GLP-1 space and Blue Jet's differentiation in peptides
Intend to give clarity in coming quarters; will focus on peptide fragments with margin resilience, not front-end generics
Q. Potential EBITDA flow-through from the ~₹30 Cr incremental sales recognition in Q2
Goods-in-transit cut-off is an ongoing issue; cannot predict closing balance for September, hence no meaningful assessment
Research and educational content only. Not investment advice.